Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can TENS, compression, or cold therapy stop chemo nerve pain?

NCT ID NCT07817979

Symptom relief Sponsor: Cumhuriyet University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing three non-drug approaches for nerve pain caused by paclitaxel, a common chemotherapy for breast cancer. The trial enrolls 140 women receiving weekly paclitaxel who develop mild nerve symptoms. Participants are assigned to TENS, compression, cryotherapy, or usual care during their infusions. The goal is to see whether any of these methods reduce nerve pain and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcutaneous electrical nerve stimulation, compression, and cryotherapy
What this could lead to
If one of these approaches works, it could give patients a simple, non-drug way to limit nerve pain during weekly paclitaxel treatment.
What could go wrong
The trial is small and single-center, so any benefit may not hold up in larger studies. TENS, compression, and cryotherapy can also be uncomfortable or impractical for some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

140 people

The number who actually took part.

Started

Apr 2025

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female and 18 years of age or older. * Diagnosed with early-stage or locally advanced breast cancer. * Receiving 12 weeks of weekly paclitaxel as adjuvant treatment. * Clinically confirmed National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 Grade 2 peripheral sensory neuropathy during the third week of paclitaxel treatment, before the third weekly infusion and randomization. * Eastern Cooperative Oncology Group performance status of 0-2 and Karnofsky Performance Status greater than 70. * Able to communicate and complete the study procedures. * Provided written informed consent to participate. Exclusion Criteria: * Peripheral neuropathy present before initiation of paclitaxel treatment. * Diabetic neuropathy or another neurological disorder that could affect the assessment of peripheral neuropathy. * Receiving paclitaxel as neoadjuvant, metastatic, or palliative treatment. * Cardiac pacemaker or another implanted electronic device contraindicating transcutaneous electrical nerve stimulation. * Active infection, open wound, serious skin lesion, or clinically significant peripheral circulatory impairment in the upper or lower extremities where the interventions would be applied. * Raynaud phenomenon, cryoglobulinemia, cold urticaria, or another clinical condition contraindicating cryotherapy. * Regularly receiving another physical intervention for chemotherapy-induced peripheral neuropathy outside the study at enrollment or planning to receive such an intervention during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Chemotherapy-induced peripheral neuropathy

Contacts and locations

Locations

  • CumhuriyetU

    Merkez, Sivas, 58010, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.